Impact of Baricitinib on Work Productivity and Indirect Costs in Adult Patients with Atopic Dermatitis: A Meta-Analysis of Clinical Trials

    S.F. Shah
    New to Baricitinib? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study found that adults with atopic dermatitis who were treated with baricitinib at doses of 2mg or 4mg experienced significant improvements in work productivity, potentially leading to substantial indirect cost savings for employers over 16 weeks.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →